指南与共识泌尿生殖MR

局灶消融后前列腺影像(PI-FAB)与跨大西洋前列腺评估建议(TARGET)在局灶治疗后前列腺磁共振成像上检测野内前列腺癌复发的比较

Comparison of the Prostate Imaging After Focal Ablation (PI-FAB) and Transatlantic Recommendations for Prostate Gland Evaluation (TARGET) for the Detection of In-Field Prostate Cancer Recurrence on Post-Focal Therapy Prostate Magnetic Resonance Imaging (MRI).
指南 / 共识 · Clin Genitourin Cancer · 2026-02-18

回顾性分析31例接受局灶治疗(HIFU或冷冻治疗)后行多参数MRI及靶向/系统穿刺的男性,比较PI-FAB与TARGET评分系统检测野内临床显著前列腺癌(Grade Group ≥ 2)复发的诊断性能。PI-FAB与TARGET的AUC分别为0.66和0.62,敏感度分别为60%和40%,特异度分别为73%和85%,NPV分别为90%和88%。两种评分系统敏感度有限但NPV较高,提示当前mpMRI解读方案在局灶治疗后监测中存在局限。

要点

  • PI-FAB与TARGET检测野内cs-PCa复发的AUC分别为0.66和0.62,诊断准确性有限。
  • PI-FAB敏感度60%、TARGET敏感度40%,两者敏感度均较低。
  • PI-FAB与TARGET的NPV分别为90%和88%,阴性结果有助于排除复发。

核心结论

  • PI-FAB与TARGET mpMRI评分系统在检测局灶治疗后野内cs-PCa复发方面敏感度有限但NPV较高,结果凸显当前mpMRI解读方案在局灶治疗后的局限性及改进监测工具以指导穿刺决策的需求。

研究设计与样本

  • 回顾性研究,2019至2023年间接受局灶治疗(HIFU或冷冻治疗)的111例男性中,31例符合分析条件(有局灶治疗后mpMRI及靶向/系统前列腺穿刺),采用PI-FAB和TARGET系统对治疗后mpMRI进行评分,参考标准为穿刺病理。

诊断标准与关键数值

  • 主要结局为穿刺检测野内cs-PCa(Grade Group ≥ 2)复发;PI-FAB的AUC为0.66,敏感度60%,特异度73%,PPV 30%,NPV 90%;TARGET的AUC为0.62,敏感度40%,特异度85%,PPV 33%,NPV 88%。

临床应用与阅片要点

  • 作者指出当前mpMRI解读方案在局灶治疗后存在局限性,需要改进监测工具以指导穿刺决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Focal therapy (FT) for intermediate-risk, clinically localized unifocal prostate cancer (PCa) offers a tissue-sparing alternative to radical treatment with fewer adverse effects. However, post-FT surveillance remains challenging due to difficulty distinguishing fibrosis from residual tumor on multiparametric MRI (mpMRI). The PI-FAB and TARGET scoring systems were proposed to improve detection of clinically significant PCa (cs-PCa) recurrence. This study compares their diagnostic performance and real-world validation.

METHODS: We retrospectively reviewed 111 men treated with FT (HIFU or cryotherapy) between 2019 and 2023, 31 of which met criteria for analysis with post-FT mpMRI and targeted/systematic prostate biopsies. Post-treatment mpMRI were scored using PI-FAB and TARGET systems. The primary outcome was detection of in-field cs-PCa (Grade Group ≥ 2) recurrence on biopsy. Diagnostic accuracy, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), was calculated for each scoring system.

RESULTS: The mean age was 67 years; 75% received HIFU and 25% cryotherapy. Eight men (26%) had cs-PCa on post-treatment biopsy, with 5 (16%) in-field recurrences. The PI-FAB and TARGET systems showed modest accuracy for in-field cs-PCa with AUCs of 0.66 and 0.62, respectively. Sensitivity was 60% (PI-FAB) and 40% (TARGET), specificity was 73% and 85%, PPV was 30% and 33%, and NPV was 90% and 88%, respectively.

CONCLUSIONS: The PI-FAB and TARGET mpMRI scoring systems demonstrate limited sensitivity but high NPV in detecting in-field cs-PCa recurrence after FT. These results highlight the limitations of current mpMRI interpretation protocols post-FT and the need for improved surveillance tools to guide biopsy decisions.

来源:Clin Genitourin Cancer,查看原文。版权归原作者所有。

引用

  1. Zhu D, Malshy K, Cheng Z, et al. Comparison of the Prostate Imaging After Focal Ablation (PI-FAB) and Transatlantic Recommendations for Prostate Gland Evaluation (TARGET) for the Detection of In-Field Prostate Cancer Recurrence on Post-Focal Therapy Prostate Magnetic Resonance Imaging (MRI). Clin Genitourin Cancer. 2026. PMID: 41807146. doi:10.1016/j.clgc.2026.102523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。